You are here: Home » Current Affairs » Coronavirus » News
Jaishankar to visit Bangladesh tomorrow ahead of PM Modi's expected visit
Business Standard

Covaxin shows 81% efficacy in phase-3 trials, says Bharat Biotech

Firm is gearing up to produce 40 million doses a month. Two Bio-safety Level-3 facilities (which can deal with deadly and contagious viruses) have been set up, third is on the way

Topics
Coronavirus | Bharat Biotech | Coronavirus Vaccine

Sohini Das  |  Mumbai 



Ram Nath Kovind
President Ram Nath Kovind receives the first dose of vaccine during the second phase of inoculation Photo: PTI

Covaxin, India’s first indigenous Covid-19 vaccine to be approved has shown an interim efficacy of 81 per cent in its phase-3 clinical trial, said on Wednesday.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Wed, March 03 2021. 18:22 IST

RECOMMENDED FOR YOU